Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Mont...(------ ------ Investing activ...),Health

Date:11/5/2009

------ ------ Investing activities: Purchase of property and equipment (3,240) (6,961) Proceeds from sales of property and equipment - 21 Purchase of investment securities (120,508) (103,605) Proceeds from sales and maturities of investment securities 67,434 58,100 Purchase of intangibles (150) - Change in restricted cash 90 (360) -- ---- Net cash used in investing activities (56,374) (52,805) ------- ------- Financing activities: Proceeds from issuance of common stock, net 1,151 1,177 Excess tax benefits from stock-based compensation awards 3,403 118 Costs paid in connection with public offerings - (764) Repurchase of common stock (11) - Proceeds from exercise of warrants - 35 --- -- Net cash provided by financing activities 4,543 566 ----- --- Net decrease in cash and cash equivalents (18,243) (28,815) Cash and cash equivalents at beginning of period 38,108 50,624 ------ ------ Cash and cash equivalents at end of period $19,865 $21,809 ------- ------- Supplemental information: Income ta
'/>"/>

SOURCE Genoptix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors